

**Bayer HealthCare**  
**Pharmaceuticals**

**RECEIVED**  
**CENTRAL FAX CENTER**

NOV 28 2006

**FAX**

**To: MAIL STOP AMENDMENT - US PATENT AND TRADEMARK OFFICE**

**Fax: (571) 273-8300**

**Number of Pages: 3 (including this cover)**

**Date: November 28, 2006**

**From: William F. Gray**

**Fax: (203) 812-6459**

**Phone: (203) 812-2712**

**E-mail: william.gray.b@bayer.com**

**Re: US Application Serial No.: 10/070,039**

**Filing Date: 10/22/2002**

**Title: Novel Dicarboxylic Acid Derivatives Having Pharmaceutical Properties**

**Attorney Docket No.: LeA 33 893**

**Art Unit: 1621**

**Examiner: Karl J. Puttlitz**

**Message:**

Attached are the following documents in connection with prosecution of this application:

- ☒ Notice Of Appeal from the examiner to the Board of Patent Appeals and Interferences
- ☐ Supplemental Amendment
- ☐ Amendment under 37 C.F.R. 1.116
- ☐ Amendment under 37 C.F.R. 1.312
- ☐ Response to Restriction and/or Election Requirement
- ☒ Petition for Extension of Time under 37 CFR 1.136(a)
- ☐ Fee Transmittal Form

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND EXEMPT FROM DISCLOSURE. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AN EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING THE MESSAGE TO THE INTENDED RECIPIENT YOU ARE HEREBY NOTIFIED THAT THE PRIVILEGED OR CONFIDENTIAL NATURE OF THIS MESSAGE IS NOT WAIVED BY INADVERTENT DISCLOSURE. ANY DISSEMINATION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL TO 400 MORGAN LANE, WEST HAVEN CONNECTICUT 06516. THANK YOU.